Skip to Content

  • Search

View Additional Section Content

A Phase III, Open-Label, Randomized, Controlled Multi-Centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA ½ Mutations

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT02282020?term=solo+3&rank=1

Principal Investigator(s)
Parviz Hanjani, M.D.

Clinical Trial Categories

  • Ovarian Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details